161 related articles for article (PubMed ID: 38722288)
1. The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment.
Cui Y; Ran R; Da Y; Zhang H; Jiang M; Qi X; Zhang W; Niu L; Zhou Y; Zhou C; Tang X; Wang K; Yan Y; Ren Y; Dong D; Zhou Y; Wang H; Gong J; Hu F; Zhao S; Zhang H; Zhang C; Yang J
J Cell Mol Med; 2024 May; 28(9):e18374. PubMed ID: 38722288
[TBL] [Abstract][Full Text] [Related]
2. Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
Wu H; Wang W; Zhang Y; Chen Y; Shan C; Li J; Jia Y; Li C; Du C; Cai Y; Zhang Y; Zhang S; Wu F
Int J Cancer; 2024 Jul; 155(2):324-338. PubMed ID: 38533706
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
4. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
5. Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
Chen P; Zhang X; Ding R; Yang L; Lyu X; Zeng J; Lei JH; Wang L; Bi J; Shao N; Shu D; Wu B; Wu J; Yang Z; Wang H; Wang B; Xiong K; Lu Y; Fu S; Choi TK; Lon NW; Zhang A; Tang D; Quan Y; Meng Y; Miao K; Sun H; Zhao M; Bao J; Zhang L; Xu X; Shi Y; Lin Y; Deng C
Adv Sci (Weinh); 2021 Nov; 8(22):e2101176. PubMed ID: 34605222
[TBL] [Abstract][Full Text] [Related]
6. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis G; Hedayat S; Vatsiou A; Jamin Y; Fernández-Mateos J; Khan K; Lampis A; Eason K; Huntingford I; Burke R; Rata M; Koh DM; Tunariu N; Collins D; Hulkki-Wilson S; Ragulan C; Spiteri I; Moorcraft SY; Chau I; Rao S; Watkins D; Fotiadis N; Bali M; Darvish-Damavandi M; Lote H; Eltahir Z; Smyth EC; Begum R; Clarke PA; Hahne JC; Dowsett M; de Bono J; Workman P; Sadanandam A; Fassan M; Sansom OJ; Eccles S; Starling N; Braconi C; Sottoriva A; Robinson SP; Cunningham D; Valeri N
Science; 2018 Feb; 359(6378):920-926. PubMed ID: 29472484
[TBL] [Abstract][Full Text] [Related]
7. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant.
Jacquemetton J; Kassem L; Poulard C; Dahmani A; De Plater L; Montaudon E; Sourd L; Morisset L; El Botty R; Chateau-Joubert S; Vacher S; Bièche I; Treilleux I; Trédan O; Marangoni E; Le Romancer M
Breast Cancer Res; 2021 May; 23(1):57. PubMed ID: 34020697
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
11. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
12. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.
Guillen KP; Fujita M; Butterfield AJ; Scherer SD; Bailey MH; Chu Z; DeRose YS; Zhao L; Cortes-Sanchez E; Yang CH; Toner J; Wang G; Qiao Y; Huang X; Greenland JA; Vahrenkamp JM; Lum DH; Factor RE; Nelson EW; Matsen CB; Poretta JM; Rosenthal R; Beck AC; Buys SS; Vaklavas C; Ward JH; Jensen RL; Jones KB; Li Z; Oesterreich S; Dobrolecki LE; Pathi SS; Woo XY; Berrett KC; Wadsworth ME; Chuang JH; Lewis MT; Marth GT; Gertz J; Varley KE; Welm BE; Welm AL
Nat Cancer; 2022 Feb; 3(2):232-250. PubMed ID: 35221336
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine.
Taverna JA; Hung CN; Williams M; Williams R; Chen M; Kamali S; Sambandam V; Hsiang-Ling Chiu C; Osmulski PA; Gaczynska ME; DeArmond DT; Gaspard C; Mancini M; Kusi M; Pandya AN; Song L; Jin L; Schiavini P; Chen CL
Lung Cancer; 2024 Apr; 190():107533. PubMed ID: 38520909
[TBL] [Abstract][Full Text] [Related]
14. Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development.
Kumari R; Xu X; Li HQ
Curr Protoc; 2022 Jul; 2(7):e431. PubMed ID: 35789132
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
16. Personalized
Pauli C; Hopkins BD; Prandi D; Shaw R; Fedrizzi T; Sboner A; Sailer V; Augello M; Puca L; Rosati R; McNary TJ; Churakova Y; Cheung C; Triscott J; Pisapia D; Rao R; Mosquera JM; Robinson B; Faltas BM; Emerling BE; Gadi VK; Bernard B; Elemento O; Beltran H; Demichelis F; Kemp CJ; Grandori C; Cantley LC; Rubin MA
Cancer Discov; 2017 May; 7(5):462-477. PubMed ID: 28331002
[TBL] [Abstract][Full Text] [Related]
17. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
18. Establishment of experimental salivary gland cancer models using organoid culture and patient-derived xenografting.
Aizawa Y; Takada K; Aoyama J; Sano D; Yamanaka S; Seki M; Kuze Y; Ramilowski JA; Okuda R; Ueno Y; Nojima Y; Inayama Y; Hatakeyama H; Hatano T; Takahashi H; Nishimura G; Fujii S; Suzuki Y; Taniguchi H; Oridate N
Cell Oncol (Dordr); 2023 Apr; 46(2):409-421. PubMed ID: 36538240
[TBL] [Abstract][Full Text] [Related]
19. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR
Hsu PY; Wu VS; Kanaya N; Petrossian K; Hsu HK; Nguyen D; Schmolze D; Kai M; Liu CY; Lu H; Chu P; Vito CA; Kruper L; Mortimer J; Chen S
Clin Cancer Res; 2018 Jan; 24(2):395-406. PubMed ID: 29079660
[No Abstract] [Full Text] [Related]
20. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
